Illumina, Inc. (ILMN): Price and Financial Metrics


Illumina, Inc. (ILMN)

Today's Latest Price: $269.05 USD

5.37 (-1.96%)

Updated Mar 27 12:00am

Add ILMN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 337 in Biotech

See all "A" rated Strong Buy stocks

ILMN Stock Summary

  • With a market capitalization of $37,364,460,000, Illumina Inc has a greater market value than 96.1% of US stocks.
  • The price/operating cash flow metric for Illumina Inc is higher than 93.46% of stocks in our set with a positive cash flow.
  • ILMN's price/sales ratio is 10.55; that's higher than the P/S ratio of 92.1% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Illumina Inc are NTES, BIDU, VMW, EA, and ANSS.
  • Visit ILMN's SEC page to see the company's official filings. To visit the company's web site, go to www.illumina.com.
ILMN Daily Price Range
ILMN 52-Week Price Range

ILMN Stock Price Chart More Charts


ILMN Price/Volume Stats

Current price $269.05 52-week high $380.76
Prev. close $274.42 52-week low $196.78
Day low $259.71 Volume 1,360,700
Day high $270.49 Avg. volume 1,504,562
50-day MA $280.11 Dividend yield N/A
200-day MA $304.30 Market Cap 39.55B

Illumina, Inc. (ILMN) Company Bio


Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.

ILMN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$269.05$140.05-49%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Illumina Inc. To summarize, we found that Illumina Inc ranked in the 25th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 48.5%. In terms of the factors that were most noteworthy in this DCF analysis for ILMN, they are:

  • Interest coverage, a measure of earnings relative to interest payments, is 22.73 -- which is good for besting 83.23% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
  • The business' balance sheet suggests that 4% of the company's capital is sourced from debt; this is greater than only 12.28% of the free cash flow producing stocks we're observing.
  • ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 55.04% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-50%
1%-49%
2%-49%
3%-48%
4%-48%
5%-47%

CAH, EHC, ENZ, VREX, and ZBH can be thought of as valuation peers to ILMN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


ILMN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ILMN Latest Social Stream


Loading social stream, please wait...

View Full ILMN Social Stream

ILMN Price Returns

1-mo 1.27%
3-mo -18.01%
6-mo -9.11%
1-year -13.40%
3-year 55.38%
5-year 44.93%
YTD -18.90%
2019 10.61%
2018 37.27%
2017 70.64%
2016 -33.30%
2015 3.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0097 seconds.